JP2010515747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010515747A5 JP2010515747A5 JP2009545660A JP2009545660A JP2010515747A5 JP 2010515747 A5 JP2010515747 A5 JP 2010515747A5 JP 2009545660 A JP2009545660 A JP 2009545660A JP 2009545660 A JP2009545660 A JP 2009545660A JP 2010515747 A5 JP2010515747 A5 JP 2010515747A5
- Authority
- JP
- Japan
- Prior art keywords
- alkenylene
- heterocycloalkyl
- alkylene
- cycloalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 54
- 125000004450 alkenylene group Chemical group 0.000 claims 52
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims 36
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 35
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 125000002947 alkylene group Chemical group 0.000 claims 20
- 125000003342 alkenyl group Chemical group 0.000 claims 18
- 125000005275 alkylenearyl group Chemical group 0.000 claims 18
- 125000005218 alkyleneheteroaryl group Chemical group 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 18
- 125000001072 heteroaryl group Chemical group 0.000 claims 18
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims 18
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000002431 hydrogen Chemical class 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 9
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 claims 7
- 206010020772 Hypertension Diseases 0.000 claims 6
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000003862 amino acid derivatives Chemical class 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 208000019553 vascular disease Diseases 0.000 claims 5
- 201000011252 Phenylketonuria Diseases 0.000 claims 4
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- FEMXZDUTFRTWPE-DZSWIPIPSA-N L-erythro-7,8-dihydrobiopterin Chemical group N1C(N)=NC(=O)C2=C1NCC([C@@H](O)[C@@H](O)C)=N2 FEMXZDUTFRTWPE-DZSWIPIPSA-N 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010022562 Intermittent claudication Diseases 0.000 claims 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 102000005506 Tryptophan Hydroxylase Human genes 0.000 claims 2
- 108010031944 Tryptophan Hydroxylase Proteins 0.000 claims 2
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 claims 2
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000008694 endothelial dysfunction Effects 0.000 claims 2
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 2
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000024883 vasodilation Effects 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 208000014249 Classic phenylketonuria Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 1
- 206010018910 Haemolysis Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000014252 Mild phenylketonuria Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- -1 aminoglucosyl Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 238000000835 electrochemical detection Methods 0.000 claims 1
- 238000001917 fluorescence detection Methods 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 230000008588 hemolysis Effects 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 229950003188 isovaleryl diethylamide Drugs 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000002858 neurotransmitter agent Substances 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 210000001147 pulmonary artery Anatomy 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 238000006722 reduction reaction Methods 0.000 claims 1
- 238000004007 reversed phase HPLC Methods 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88472707P | 2007-01-12 | 2007-01-12 | |
| PCT/US2008/050637 WO2008089008A2 (en) | 2007-01-12 | 2008-01-09 | Tetrahydrobiopterin prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010515747A JP2010515747A (ja) | 2010-05-13 |
| JP2010515747A5 true JP2010515747A5 (cg-RX-API-DMAC7.html) | 2011-03-03 |
Family
ID=39535519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009545660A Pending JP2010515747A (ja) | 2007-01-12 | 2008-01-09 | テトラヒドロビオプテリンプロドラッグ |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20100016328A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2114944A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010515747A (cg-RX-API-DMAC7.html) |
| AR (1) | AR064874A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008206486C1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2675134A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2008000094A1 (cg-RX-API-DMAC7.html) |
| PE (1) | PE20081612A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW200843778A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008089008A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011508775A (ja) | 2008-01-03 | 2011-03-17 | ビオマリン プハルマセウトイカル インコーポレイテッド | Ｂｈ４応答性状態を治療するためのプテリン類似体 |
| MX2010007452A (es) | 2008-01-07 | 2010-08-18 | Biomarin Pharm Inc | Metodo para sintetizar tetrahidrobiopterin. |
| JP5066756B2 (ja) * | 2010-04-22 | 2012-11-07 | 学校法人日本大学 | 脳機能障害予防・改善用の薬剤及び飲食物 |
| JP5972911B2 (ja) | 2011-02-18 | 2016-08-17 | アレクシオン ファーマ インターナショナル エスアーアールエル | モリブドプテリン前駆体ｚ誘導体を合成するための方法 |
| EP2751071B1 (en) * | 2011-08-31 | 2019-11-27 | Jill C. Milne | Fatty acid amides, compositions and methods of use |
| US9303038B2 (en) | 2011-09-06 | 2016-04-05 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy and neurological diseases |
| JP6591748B2 (ja) * | 2011-10-31 | 2019-10-16 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 自閉症の処置のための方法および組成物 |
| US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
| EP2847169A4 (en) | 2012-05-07 | 2015-09-30 | Cellix Bio Private Ltd | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS |
| JP2015522531A (ja) | 2012-05-07 | 2015-08-06 | セリックスビオ プライヴェート リミテッド | 神経筋疾患及び神経変性疾患の治療のための組成物及び方法 |
| US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
| WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
| WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
| US9522884B2 (en) | 2012-05-08 | 2016-12-20 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic disorders |
| WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| WO2013168016A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
| US9315461B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9498461B2 (en) | 2012-05-23 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
| US9227974B2 (en) | 2012-05-23 | 2016-01-05 | Cellex Bio Private Limited | Compositions and methods for the treatment of respiratory disorders |
| SG11201407322QA (en) | 2012-05-23 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of multiple sclerosis |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| CA2873104A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of mucositis |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2014020480A2 (en) | 2012-08-03 | 2014-02-06 | Mahesh Kandula | Compositions and methods for the treatment migraine and neurologic diseases |
| US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
| WO2014037834A2 (en) | 2012-09-08 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of inflammation and lipid disorders |
| WO2014041446A2 (en) * | 2012-09-17 | 2014-03-20 | Mahesh Kandula | Compositions and methods for the treatment of metabolic diseases |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| CA2914461A1 (en) | 2013-06-04 | 2014-12-11 | Cellixbio Private Limited | Compositions and methods for the treatment of diabetes and pre-diabetes |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| SG11201706952VA (en) | 2014-09-26 | 2017-10-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of epilepsy and neurological disorders |
| WO2016051420A1 (en) | 2014-09-29 | 2016-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| CN107108535B (zh) | 2014-10-27 | 2020-04-28 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐 |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| EP3242869B1 (en) | 2015-01-06 | 2021-10-27 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammation and pain |
| CA3018311A1 (en) * | 2016-04-01 | 2017-10-05 | University Of Utah Research Foundation | Methods of treating peripheral vascular diseases, including systemic sclerosis vasculopathy |
| GB2566516A (en) | 2017-09-15 | 2019-03-20 | Univ Oxford Innovation Ltd | Electrochemical recognition and quantification of cytochrome c oxidase expression in bacteria |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| WO2019175332A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity |
| US11471963B2 (en) | 2019-01-25 | 2022-10-18 | Black & Decker Inc. | Reciprocating saw blade |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2601215A (en) * | 1948-03-17 | 1952-06-17 | American Cyanamid Co | Process of preparing dihydropterins |
| US3505329A (en) * | 1968-02-06 | 1970-04-07 | Smithkline Corp | Process for the synthesis of biopterin |
| JPS574990A (en) * | 1980-05-09 | 1982-01-11 | Bisukonchiini Matsukusu | Polyacylated tetrahydropterin derivative and manufacture |
| JPS5883691A (ja) * | 1981-11-13 | 1983-05-19 | Kanegafuchi Chem Ind Co Ltd | １′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法 |
| CH651755A5 (en) * | 1982-03-03 | 1985-10-15 | Kanegafuchi Chemical Ind | Use of pterin derivatives |
| GB8318833D0 (en) * | 1983-07-12 | 1983-08-10 | Wellcome Found | Chemical compounds |
| JPS5976086A (ja) * | 1982-09-20 | 1984-04-28 | ザ ウエルカム フアウンデ−シヨン リミテツド | プテリジン化合物 |
| JPS59112987A (ja) * | 1982-12-20 | 1984-06-29 | Kanegafuchi Chem Ind Co Ltd | １′，２′―ジアシル―（６ｒ，ｓ）―５，６，７，８―テトラヒドロ―ｌ―ビオプテリンおよびその製法 |
| US5196533A (en) * | 1983-04-11 | 1993-03-23 | South Alabama Medical Science Foundation, Usa | Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines |
| US4587340A (en) * | 1983-09-19 | 1986-05-06 | Burroughs Wellcome Co. | Biopterin analogs |
| JPS60178887A (ja) * | 1984-02-23 | 1985-09-12 | Kanegafuchi Chem Ind Co Ltd | ５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法 |
| JPS60199889A (ja) * | 1984-03-24 | 1985-10-09 | Kanegafuchi Chem Ind Co Ltd | ５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法 |
| US4550109A (en) * | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
| US4713454A (en) * | 1985-01-28 | 1987-12-15 | Shiratori Pharmaceutical Co., Ltd. | Preparation process of (6R)-tetrahydro-L-biopterin |
| ES287056Y (es) * | 1985-05-24 | 1988-06-16 | Salvador Herrero Manuel Ram | Comprobador de condensadores y bobinas de vehiculos automo- viles |
| JPS61277618A (ja) * | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| JPS61293983A (ja) * | 1985-06-22 | 1986-12-24 | Kanegafuchi Chem Ind Co Ltd | ５ｎ−アシルテトラヒドロプテリン化合物 |
| GB8719367D0 (en) * | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
| CA1334654C (en) * | 1987-11-30 | 1995-03-07 | Masayasu Kurono | Intermediates for synthesizing bh _and its derivatives |
| DE68922903T2 (de) * | 1988-12-19 | 1995-11-23 | Wellcome Found | Antivirale Pyrimidin- und Purinverbindungen, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate. |
| US5198547A (en) * | 1992-03-16 | 1993-03-30 | South Alabama Medical Science Foundation, Usa | Process for N5-formylating tetrahydropteridines |
| DE4308739C1 (de) * | 1993-03-19 | 1994-06-23 | Henning Berlin Gmbh | Pterinderivate, ihre Herstellung und ihre Verwendung |
| DE4418097A1 (de) * | 1994-05-24 | 1995-11-30 | Cassella Ag | Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase |
| ES2177654T3 (es) * | 1994-08-05 | 2002-12-16 | Suntory Ltd | Remedio contra la degeneracion espinocerebelosa. |
| WO1998004558A1 (en) * | 1996-07-31 | 1998-02-05 | Artemis, Inc. | Active oxygen scavengers containing pterin derivatives |
| JP4306825B2 (ja) * | 1998-02-27 | 2009-08-05 | アスビオファーマ株式会社 | インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤 |
| DE19944767A1 (de) * | 1999-09-17 | 2001-03-29 | Vasopharm Biotech Gmbh & Co Kg | N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20030078231A1 (en) * | 2001-06-22 | 2003-04-24 | Wilburn Michael D. | Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties |
| DE10260263A1 (de) * | 2002-12-20 | 2004-07-15 | Biocrates Life Sciences Gmbh | Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen |
| US20050137141A1 (en) * | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
| US20070167353A1 (en) * | 2003-10-24 | 2007-07-19 | John Hilfinger | Prodrug composition |
| AU2004290692A1 (en) * | 2003-11-17 | 2005-06-02 | Biomarin Pharmaceutical Inc. | Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
| PL1708690T3 (pl) * | 2003-11-17 | 2017-01-31 | Biomarin Pharmaceutical Inc. | Leczenie fenyloketonurii za pomocą BH4 |
| US7067659B2 (en) * | 2004-04-23 | 2006-06-27 | Duke University | Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof |
| MX2007005039A (es) * | 2004-11-17 | 2007-06-19 | Biomarin Pharm Inc | Formulacion de tableta estable. |
| US20060194800A1 (en) * | 2005-01-07 | 2006-08-31 | University Of Strathclyde | Pteridine derivatives as nitric oxide synthase activators |
| US20060194808A1 (en) * | 2005-01-14 | 2006-08-31 | Chronorx Llc, An Alaska Limited Liability Company | Clinical applications of tetrahydrobiopterin, lipoic acid and their salts and methods of preparing tetrahydrobiopterin bis-lipoate |
| JP2011508775A (ja) * | 2008-01-03 | 2011-03-17 | ビオマリン プハルマセウトイカル インコーポレイテッド | Ｂｈ４応答性状態を治療するためのプテリン類似体 |
-
2008
- 2008-01-09 EP EP08705803A patent/EP2114944A2/en not_active Withdrawn
- 2008-01-09 CA CA002675134A patent/CA2675134A1/en not_active Abandoned
- 2008-01-09 JP JP2009545660A patent/JP2010515747A/ja active Pending
- 2008-01-09 AU AU2008206486A patent/AU2008206486C1/en not_active Ceased
- 2008-01-09 WO PCT/US2008/050637 patent/WO2008089008A2/en not_active Ceased
- 2008-01-11 CL CL200800094A patent/CL2008000094A1/es unknown
- 2008-01-11 AR ARP080100139A patent/AR064874A1/es unknown
- 2008-01-11 TW TW097101226A patent/TW200843778A/zh unknown
- 2008-01-11 PE PE2008000117A patent/PE20081612A1/es not_active Application Discontinuation
-
2009
- 2009-07-09 US US12/500,537 patent/US20100016328A1/en not_active Abandoned
-
2011
- 2011-09-16 US US13/235,115 patent/US20120022072A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010515747A5 (cg-RX-API-DMAC7.html) | ||
| JP7155315B2 (ja) | Ａｃｃ阻害剤およびその固体形態を調製するためのプロセス | |
| US11013726B2 (en) | Substituted pyridinone-containing trycyclic compounds, and methods using same | |
| JP2021185206A (ja) | チエノピリミジンジオンａｃｃ阻害剤の固体形態およびその生成のための方法 | |
| WO2018043747A1 (ja) | 抗ｂ型肝炎ウイルス剤 | |
| JP2009132723A (ja) | Ｎｏｓの機能低下が寄与する疾患の予防または治療剤 | |
| KR20150054795A (ko) | B형 간염 바이러스 감염의 치료 및 예방을 위한 6-아미노산 헤테로아릴다이하이드로피리미딘 | |
| RU2010147404A (ru) | Замещенные дигидропиразолоны в качестве ингибиторов hif-пролил-4-гидроксилазы | |
| RU2010132278A (ru) | Аналоги птерина для лечения состояния, чувствительного к вн4 | |
| WO2016129583A1 (ja) | 乳酸脱水素酵素阻害剤およびそれを含有する抗てんかん剤 | |
| CN109641890B (zh) | 异柠檬酸脱氢酶(idh)抑制剂 | |
| CN116693447B (zh) | 酮酰胺类衍生物及其制药用途 | |
| US10358447B2 (en) | Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same | |
| CN108350007B (zh) | 一种取代的腺嘌呤化合物及其药物组合物 | |
| KR20160042140A (ko) | 약제의 생물활성 향상 방법 | |
| TWI344959B (en) | Treatment of hepatitis c virus infection with sesquiterpene lactones | |
| EP3189060B1 (fr) | Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques comme inhibiteurs de la ftl3 and jak | |
| US20120142694A1 (en) | Substituted 4-hydroxypyrimidine-5-carboxamides | |
| CN1583747A (zh) | 蝶呤类一氧化氮合酶抑制剂 | |
| WO2011144924A1 (en) | Amine or amid analogues of sanglifehrin | |
| US10550084B2 (en) | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same | |
| CN110023298B (zh) | 异柠檬酸脱氢酶(idh)抑制剂 | |
| TW202203914A (zh) | 特別用於治療b型肝炎和d型肝炎之抗病毒化合物 | |
| EP3543238B1 (en) | Nucleoside derivatives having anti-viral activity | |
| CN108290892A (zh) | 一种取代的黄嘌呤及其药物组合物 |